Serum APRIL, a potential tumor marker in pancreatic cancer

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1715-1719

  Wang, Feng ^a   Chen, Lin ^b   Ding, Weifeng ^a   Wang, Guihua ^a   Wu, Yueping ^b   Wang, Jingchun ^a   Luo, Leilei ^b   Cong, Hui ^a   Wang, Yueguo ^a   Ju, Shaoqing ^a   Shao, Jianguo ^b   Wang, Huimin ^a  

^a NANTONG UNIVERSITY   (China)

^b Third People's Hospital of Nantong City   (China)

Author keywords

a proliferation inducing ligand; carbohydrate antigen (CA)19 9; carcinoembryonic antigen (CEA); pancreatic cancer

Indexed keywords

APRIL PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 80054934507     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.608     Document Type: Article

References (21)

1. Li J, Wientjes MG, Au JL. Pancreatic cancer: Pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32.
2. Pliarchopoulou K, Pectasides D. Pancreatic cancer: Current and future treatment strategies. Cancer Treat Rev 2009;35:431-6.
3. Sarkar FH, Banerjee S, Li Y. Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 2007;224: 326-36. (Pubitemid 47575667)
4. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188: 1185-90. (Pubitemid 28443341)
5. Gu D, Ge J, Du W, Xue F, Chen Z, Zhao H, et al. Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications. Autoimmunity 2009; 42:692-8.
6. Kimberley FC, van Bostelen L, Cameron K, Hardenberg G, Marquart JA, Hahne M, et al. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J 2009; 23:1584-95.
7. Sun B, Wang H, Wang X, Huang H, Ding W, Jing R, et al. A proliferation-inducing ligand: A new biomarker for non-small cell lung cancer. Exp Lung Res 2009;35:486-500.
8. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 2006;80:697-704. (Pubitemid 44835884)
9. Ding W, Wang J, Sun B, Ju S, Yuan H, Wang X, et al. APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem 2009;42:1694-8.
10. Planelles L, Medema JP, Hahne M, Hardenberg G. The expanding role of APRIL in cancer and immunity. Curr Mol Med 2008;8:829-44.
11. Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: Link with tumor progression. BMC Cancer 2009;9:83.
12. Wang F, Chen L, Mao ZB, Shao JG, Tan C, Huang WD. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep 2008;20:135-9.
13. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 2009;9:1487-97.
14. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro R, et al. APRIL promotes B-1 cellassociated neoplasm. Cancer Cell 2004;6:399-408. (Pubitemid 39361440)
15. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007;109:331-8. (Pubitemid 46053074)
16. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 2005;12:637-48. (Pubitemid 40767166)
17. Ding W, Ju S, Jiang S, Zhu L, Wang Y, Wang H. Reduced APRIL expression induces cellular senescence via a HSPGdependent pathway. Pathol Oncol Res 2009;15:693-701.
18. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, et al. Identification of proteoglycans as the APRILspecific binding partners. J Exp Med 2005;201:1375-83. (Pubitemid 40664082)
19. Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, et al. Elevated serum APRIL levels in patients with systemic sclerosis: Distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007;34:2056-62. (Pubitemid 47548210)
20. Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, et al. Increased serum levels of a proliferationinducing ligand in patients with bullous pemphigoid. J Dermatol Sci 2007;46:53-60. (Pubitemid 46366633)
21. Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al. BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev 2010;9:165-9.